Search research articles
Contact Us
Filters
Showing results (171-180 of 310) with videos related to
Page
of 31
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
July 20, 2016
Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database
Daniel A Morgenstern, Wendy B London, Derek Stephens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 27, 2014
Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project
Kieuhoa T Vo, Katherine K Matthay, John Neuhaus, et al.
Gene Therapy
|
September 14, 2007
Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts
C F McTiernan, M A Mathier, X Zhu, et al.
Pediatric Blood & Cancer
|
November 28, 2018
The challenge of defining "ultra-high-risk" neuroblastoma
Daniel A Morgenstern, Rochelle Bagatell, Susan L Cohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 5, 2011
Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age
Denah R Taggart, Wendy B London, Mary Lou Schmidt, et al.
Pediatric Blood & Cancer
|
October 22, 2008
Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group
Julie R Park, Judith G Villablanca, Wendy B London, et al.
Pediatric Blood & Cancer
|
December 19, 2017
Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma
Lillian M Guenther, R Grant Rowe, Patricia T Acharya, et al.
British Journal of Cancer
|
April 30, 2009
International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee
P F Ambros, I M Ambros, G M Brodeur, et al.
The American Journal of Surgical Pathology
|
March 19, 2021
Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group
Asuka Kawano, Florette K Hazard, Bill Chiu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 27, 2013
Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group
Gregory A Yanik, Marguerite T Parisi, Barry L Shulkin, et al.
Page
of 31
Search research articles
Search
Showing results (171-180 of 310) with videos related to
Sort By:
Page
of 31
European Journal of Cancer (Oxford, England : 1990)
|
July 20, 2016
Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database
Daniel A Morgenstern, Wendy B London, Derek Stephens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 27, 2014
Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project
Kieuhoa T Vo, Katherine K Matthay, John Neuhaus, et al.
Gene Therapy
|
September 14, 2007
Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts
C F McTiernan, M A Mathier, X Zhu, et al.
Pediatric Blood & Cancer
|
November 28, 2018
The challenge of defining "ultra-high-risk" neuroblastoma
Daniel A Morgenstern, Rochelle Bagatell, Susan L Cohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 5, 2011
Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age
Denah R Taggart, Wendy B London, Mary Lou Schmidt, et al.
Pediatric Blood & Cancer
|
October 22, 2008
Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group
Julie R Park, Judith G Villablanca, Wendy B London, et al.
Pediatric Blood & Cancer
|
December 19, 2017
Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma
Lillian M Guenther, R Grant Rowe, Patricia T Acharya, et al.
British Journal of Cancer
|
April 30, 2009
International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee
P F Ambros, I M Ambros, G M Brodeur, et al.
The American Journal of Surgical Pathology
|
March 19, 2021
Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group
Asuka Kawano, Florette K Hazard, Bill Chiu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 27, 2013
Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group
Gregory A Yanik, Marguerite T Parisi, Barry L Shulkin, et al.
Page
of 31